Amicus Therapeutics, Inc.

News and overview for Amicus Therapeutics, Inc.

Amicus Therapeutics' shares fall following move to end Shire partnership, cut jobs
Sun (Baltimore), The | 25 days 15 hours 55 minutes ago
Shares of biotechnology company Amicus Therapeutics Inc. fell Friday after the company said it ended a partnership with Shire PLC to jointly develop treatments for genetic disorders, while cutting jobs amid the resignation of its chief financial officer.


Amicus shares fall on closed partnership, job cuts
Richmond Times-Dispatch (Va.) | 25 days 16 hours 6 minutes ago
NEW YORK (AP) -- Shares of biotechnology company Amicus Therapeutics Inc. fell Friday after the company said it ended a partnership with Shire PLC to jointly develop treatments for genetic disorders, while cutting jobs amid the resignation of its chief financial officer.


Amicus Therapeutics Announces Third Quarter 2009 Financial Results and Strategic Business Updates [Press Release]
PRNewswire | 26 days 7 hours 22 minutes ago
CRANBURY, N.J., Oct. 29 /PRNewswire-FirstCall/ -- Amicus Therapeutics


Amicus Therapeutics' shares fall following move to end Shire partnership, cut jobs -- South Florida Sun-Sentinel.com
Sun-Sentinel (Fort Lauderdale, Fla.) | 25 days 16 hours 17 minutes ago
NEW YORK (AP) — Shares of biotechnology company Amicus Therapeutics Inc. fell Friday after the company said it ended a partnership with Shire PLC to jointly develop treatments for genetic disorders, while cutting jobs amid the resignation of its chief financial officer.


Amicus Therapeutics Announces Second Quarter 2009 Financial Results [Press Release]
PRNewswire | 111 days 12 hours 25 minutes ago
...Act of 1995. Table 1 Amicus Therapeutics, Inc. (a development stage...22,615,951 Table 2 Amicus Therapeutics, Inc. Reconciliation of GAAP...22,618,026 Table 3 Amicus Therapeutics, Inc. Reconciliation of GAAP...


SHIRE PLC - Half Yearly Report [Press Release]
PRNewswire | 95 days 16 hours 55 minutes ago
Half Yearly Report


Amicus Shares Fall on Closed Partnership, Job Cuts
ABC News | 25 days 16 hours 2 minutes ago
Amicus Therapeutics' shares fall following move to end Shire partnership, cut jobs


Amicus shares fall on closed partnership, job cuts - National Business - MiamiHerald.com
Miami Herald, The | 25 days 15 hours 46 minutes ago
NEW YORK -- Shares of biotechnology company Amicus Therapeutics Inc. fell Friday after the company said it ended a partnership with Shire PLC to jointly develop treatments for genetic disorders, while cutting jobs amid the resignation of its chief financial officer.


Amicus Therapeutics Appoints Margaret G. McGlynn, R.Ph., to Board of Directors [Press Release]
PRNewswire | 21 days 13 hours 27 minutes ago
...FirstCall/ -- Amicus Therapeutics today announced...Merck & Co., Inc. John F...President and CEO of Amicus Therapeutics stated, "Margie...invaluable to Amicus as we execute...Merck & Co., Inc. after more than...


Shire announces third quarter 2009 financial results
News-Medical.Net | 25 days 1 hour 11 minutes ago
Shire plc (LSE: SHP, NASDAQ: SHPGY) the global specialty biopharmaceutical company, announces results for the three months to September 30, 2009.


Amicus Therapeutics Announces Preliminary Results of Phase 2 Study with Plicera(TM) for Gaucher Disease [Press Release]
PRNewswire | 53 days 11 hours 55 minutes ago
...European Union. Amicus Therapeutics is a biopharmaceutical...developing novel, oral therapeutics known as pharmacological...increased activity. Amicus is initially targeting...Genetic Therapies, Inc., a wholly-owned...


Phase Forward to Host Eighth Annual International Users Conference, November 3-5, Boston [Press Release]
Business Wire | 22 days 18 hours 27 minutes ago
Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, will host its eighth annual International Users Conference (IUC) this week. Under the theme “Powering More Possibilities,” the conference will be held at the Sheraton Boston Hotel in Boston.


Amicus Therapeutics Announces Plan to Initiate Phase 1 Study of AT2220 for Pompe Disease [Press Release]
PRNewswire | 55 days 20 hours 23 minutes ago
...the United States. Amicus Therapeutics is a biopharmaceutical...developing novel, oral therapeutics known as pharmacological...increased activity. Amicus is initially targeting...Genetic Therapies, Inc., a wholly-owned...


Movers roundup: Las Vegas Sands, Monster
Forbes | 25 days 13 hours 30 minutes ago
Among the stock activity stories for Friday, Oct. 30, from AP Financial News:Shares of Las Vegas Sands Corp. ( LVS - news - people ) rose as the casino operator received approval for its Hong Kong initial public offering and investors latched on to upbeat comments made by CEO Sheldon Adelson.


Cylex, Inc. Appoints Brad L. Stewart as Chief Executive Officer and Chairman of the Board [Press Release]
PRNewswire | 75 days 18 hours 54 minutes ago
...cancer patients; Cerexa Inc., one of the largest biotech...acquisitions of 2007; DexCom Inc., the largest diagnostic IPO of 2005; and Amicus Therapeutics, a pioneer of next-generation...Calibra Medical, Chimerix, Inc., Liquidia Technologies...





 1  2  

15 Results

Sign up for ANA SmartBrief



Designed specifically for nurses, ANA SmartBrief is a FREE, daily e-mail newsletter. It provides the latest news and information you need to stay informed about important health care issues impacting the nursing profession. Sign up for your very own free subscription to ANA SmartBrief. Learn more

Company Overview


Company: Amicus Therapeutics, Inc.
Industry: Biopharmaceuticals & Biotherapeutics
Website: http://www.amicustherapeutics.com

Amicus Therapeutics develops drugs that treat rare genetic diseases known as lysosomal storage disorders. The company's enzyme replacement therapies are designed to target defective proteins and restore their functions. Its lead drug candidate, Amigal, is aimed at aiding patients with Fabry disease, whose symptoms include skin rashes, impaired sweating, and gastrointestinal, heart, and kidney problems that vary in severity. Amicus is also developing drugs to treat Gaucher disease, a disorder that can cause anemia and skeletal lesions, and Pompe disease, which causes muscle weakness and impairs breathing, mobility, and heart function.


Key Numbers

Sales in U.S. Dollars (mil.) 15 (2008)
One-year % Growth in Sales 739.0 (2008)
Net Income in U.S. Dollars (mil.) -39.4 (2008)
One-year % Growth in Net Income 0.0 (2008)
Number of Employees 115 (2008)
One-year % Growth in Number of Employees 0.0 (2008)
Fiscal Year-End December